MBK Partners has seen its sale of a 60% stake in CNS fall through again, underscoring the difficulty for private equity firms looking to exit Taiwan in the face of regulatory challenges.
Some investors feel China's technology sector has been overfunded and that even some unicorns – private companies worth $1 billion-plus – will die off.